- Home
- ASM vs CSTL Comparison
ASM vs CSTL Comparison
Compare ASM & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASM
- CSTL
- Stock Information
- Founded
- ASM 1968
- CSTL 2007
- Country
- ASM Canada
- CSTL United States
- Employees
- ASM N/A
- CSTL N/A
- Industry
- ASM Metal Mining
- CSTL Medical Specialities
- Sector
- ASM Basic Materials
- CSTL Health Care
- Exchange
- ASM Nasdaq
- CSTL Nasdaq
- Market Cap
- ASM 612.8M
- CSTL 697.9M
- IPO Year
- ASM N/A
- CSTL 2019
- Fundamental
- Price
- ASM $4.58
- CSTL $21.79
- Analyst Decision
- ASM Strong Buy
- CSTL Strong Buy
- Analyst Count
- ASM 3
- CSTL 6
- Target Price
- ASM $3.73
- CSTL $37.67
- AVG Volume (30 Days)
- ASM 5.5M
- CSTL 449.4K
- Earning Date
- ASM 11-11-2025
- CSTL 11-03-2025
- Dividend Yield
- ASM N/A
- CSTL N/A
- EPS Growth
- ASM 1940.36
- CSTL N/A
- EPS
- ASM 0.11
- CSTL N/A
- Revenue
- ASM $79,639,000.00
- CSTL $346,269,000.00
- Revenue This Year
- ASM $33.26
- CSTL N/A
- Revenue Next Year
- ASM $27.16
- CSTL N/A
- P/E Ratio
- ASM $44.67
- CSTL N/A
- Revenue Growth
- ASM 53.08
- CSTL 20.40
- 52 Week Low
- ASM $0.85
- CSTL $14.59
- 52 Week High
- ASM $4.75
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- ASM 63.68
- CSTL 49.78
- Support Level
- ASM $4.00
- CSTL $22.54
- Resistance Level
- ASM $4.30
- CSTL $24.74
- Average True Range (ATR)
- ASM 0.24
- CSTL 1.14
- MACD
- ASM -0.01
- CSTL -0.29
- Stochastic Oscillator
- ASM 76.67
- CSTL 27.33
About ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.